Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

SCV-07 (SciClone Pharmaceuticals/Verta).

Richard J Aspinall¹, Paul J Pockros

¹Scripps Clinic, Division of Gastroenterology/Hepatology, La Jolla, CA 92037, USA. Aspinall.Richard@scrippshealth.org

Current Opinion in Investigational Drugs (London, England : 2000)

|February 28, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Guideline for the management of hepatitis B and C infection and subsequent liver disease surveillance (where indicated) in people with congenital bleeding disorders: A joint guideline from the British Society of Haematology and the British Viral Hepatitis Group.

British journal of haematology·2025

Same author

Implementation of a care bundle improves PBC management.

JHEP reports : innovation in hepatology·2025

Same author

Lessons From COBALT: Will the Bell Also Toll for Thee?

The American journal of gastroenterology·2024

Same author

Latent Autoimmune Diabetes in Adults (LADA) Occurring in a Patient with Primary Biliary Cholangitis.

The American journal of medicine·2024

Same author

Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACT-AVB trial).

BMJ open gastroenterology·2024

Same author

Novel, nurse-led early postdischarge clinic is associated with fewer readmissions and lower mortality following hospitalisation with decompensated cirrhosis.

Frontline gastroenterology·2024

SciClone Pharmaceuticals and Verta are developing SCV-07, an immunomodulator, for tuberculosis and hepatitis C. Phase II clinical trials are currently underway to evaluate its efficacy.

Area of Science:

Immunology
Infectious Diseases
Pharmacology

Background:

Tuberculosis (TB) remains a significant global health challenge.
Hepatitis C virus (HCV) infection affects millions worldwide.
Novel immunomodulatory agents are needed for effective treatment.

Purpose of the Study:

To evaluate the potential of SCV-07 as a therapeutic agent.
To investigate the efficacy of SCV-07 in treating tuberculosis.
To assess the safety and efficacy of SCV-07 in patients with hepatitis C virus infection.

Main Methods:

SCV-07 is a lead immunomodulator developed by Verta.
The compound is undergoing Phase II clinical trials.
Ongoing trials assess treatment for tuberculosis and hepatitis C.

Related Experiment Videos

Main Results:

Data from ongoing Phase II trials are pending.
Preliminary assessments of SCV-07's immunomodulatory effects are being analyzed.
The development is a collaboration between SciClone Pharmaceuticals and Verta.

Conclusions:

SCV-07 shows potential for treating infectious diseases like TB and HCV.
Further clinical evaluation is necessary to confirm its therapeutic value.
The ongoing Phase II trials are critical for determining the future of SCV-07.